Can immunotherapy 'clip the force field' of gastrointestinal tumors? Dr John Marshall and experts say yes and will discuss advances during the Ruesch Symposium 2014, December 5, Washington, DC.

Dr David Johnson takes you on a whirlwind tour of the practice-changing highlights from this year's American College of Gastroenterology meeting.

With products coming and going, what is the best preparation for bowel cleansing before colonoscopy?

'Good bacteria' are appealing, but should we rush to recommend them to prevent antibiotic-associated diarrhea?

A new multitargeted stool-based screening test could be the answer for patients who avoid colonoscopy. Dr. David Johnson offers commentary, and a couple of caveats, on its use in clinical practice.

Is it time to consider psychological approaches to irritable bowel syndrome an important component of care?

Patients might not bring them up, but hemorrhoids and anal fissures, along with their consequences, are common complaints. Here's how to evaluate and treat them.

Dr. John Marshall questions why the survival rate in a large phase 3 trial presented at ASCO was nearly double the survival rates achieved by earlier trials while using the same medicines.

Dr. David Johnson discusses the newly approved drug for both ulcerative colitis and Crohn disease that more closely targets gut inflammation, and may be a boon for patients.

Dr. David Kerr discusses strategies for increasing CRC screening in underserved populations in the United States, as proposed by a coalition of experts in cancer control and prevention.